Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing. The initiation of the Phase I study, which had been expected about now, marks further progress in the race to develop a vaccine against a disease has killed more than 8,000 people in West Africa since last year.